uniQure’s (QURE) “Buy” Rating Reiterated at HC Wainwright

uniQure (NASDAQ:QURE)‘s stock had its “buy” rating reiterated by equities research analysts at HC Wainwright in a note issued to investors on Tuesday,Benzinga reports. They presently have a $70.00 target price on the biotechnology company’s stock.

A number of other research analysts also recently issued reports on QURE. Royal Bank of Canada restated an “outperform” rating and set a $24.00 target price on shares of uniQure in a research report on Tuesday, January 21st. Leerink Partners upped their target price on uniQure from $26.00 to $44.00 and gave the stock an “outperform” rating in a research note on Wednesday, December 11th. The Goldman Sachs Group lifted their price target on uniQure from $9.00 to $20.00 and gave the company a “neutral” rating in a research report on Thursday, December 12th. Guggenheim reaffirmed a “buy” rating on shares of uniQure in a research note on Wednesday, December 11th. Finally, Stifel Nicolaus boosted their target price on shares of uniQure from $12.00 to $32.00 and gave the company a “buy” rating in a research note on Monday, December 16th. One analyst has rated the stock with a sell rating, three have assigned a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $38.89.

uniQure Stock Performance

Shares of NASDAQ:QURE traded down $0.08 during trading on Tuesday, hitting $10.83. The stock had a trading volume of 920,097 shares, compared to its average volume of 1,024,768. The company has a quick ratio of 6.51, a current ratio of 6.51 and a debt-to-equity ratio of 0.92. uniQure has a 12-month low of $3.73 and a 12-month high of $19.18. The stock has a market capitalization of $527.64 million, a price-to-earnings ratio of -2.16 and a beta of 0.38. The stock has a 50-day simple moving average of $14.92 and a two-hundred day simple moving average of $9.86.

Insider Buying and Selling

In other news, CFO Christian Klemt sold 14,341 shares of the company’s stock in a transaction on Tuesday, February 25th. The shares were sold at an average price of $10.70, for a total transaction of $153,448.70. Following the completion of the sale, the chief financial officer now owns 152,372 shares of the company’s stock, valued at $1,630,380.40. This represents a 8.60 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Matthew C. Kapusta sold 3,418 shares of the firm’s stock in a transaction dated Monday, December 9th. The stock was sold at an average price of $7.63, for a total transaction of $26,079.34. Following the completion of the transaction, the chief executive officer now directly owns 597,915 shares in the company, valued at approximately $4,562,091.45. This represents a 0.57 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 55,915 shares of company stock worth $588,112. 4.74% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On uniQure

A number of institutional investors have recently added to or reduced their stakes in the stock. RTW Investments LP acquired a new stake in shares of uniQure during the 3rd quarter worth approximately $49,000. Atria Investments Inc acquired a new stake in uniQure during the third quarter worth $53,000. Quarry LP purchased a new stake in uniQure in the third quarter valued at $58,000. Connor Clark & Lunn Investment Management Ltd. acquired a new position in shares of uniQure in the 3rd quarter valued at $69,000. Finally, Twin Tree Management LP purchased a new position in shares of uniQure during the 4th quarter worth $77,000. Hedge funds and other institutional investors own 78.83% of the company’s stock.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.